Eastman Chemical Company
NYSE:EMNChemicals
-$1.16 today
- Market cap
- $7.13B
- Beta
- 1.07
- P/E (TTM)
- 20.6
- EPS (TTM)
- $3.50
- Dividend yield
- 4.65%
Volume 1.38M
Average 1.33M
EMN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Eastman Chemical CompanyNYSE: EMN
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of $442M rose 25.6% year over year, ahead of the -26.3% change in trailing-twelve-month EBITDA. Sequentially, it rose 39.9% from the prior quarter. Over 3 fiscal years it compounded at -7.6% a year.
Context
- EBITDA amounted to 14.7% of revenue in FY2025, down 4.5 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 11 analysts of $1.61B (+24.8%) for the fiscal year ending Dec 2026, a step up from the -28.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $442M+39.9% QoQ
- Last fiscal yearDec 2025
- $1.29B-28.5% YoY
- LTMJun 2026
- $1.27B-26.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +25.6% | +44.5% | +18.9 pp |
| 1 year | -28.5% | +24.8% | +53.3 pp |
| 3-year CAGR | -7.6% | +11.6% | +19.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 1.29B USD
- Year-over-year change
- -28.5%
- 4-year CAGR
- -8.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.29B | -28.5% |
| FY2024 | 2024-12-31 | 1.8B | -0.2% |
| FY2023 | 2023-12-31 | 1.81B | +10.5% |
| FY2022 | 2022-12-31 | 1.64B | -9.7% |
| FY2021 | 2021-12-31 | 1.81B | — |
EBITDA vs competitors
How EMN compares with its peers on the latest reported figures
- EMN's LTM Jun 2026 EBITDA of $1.27B is the 2nd highest of the 11 companies compared; the peer median is $423M.
- Its year-over-year change of -26.3% is the 9th highest of 11, against a peer median of -3.4%.
- EBITDA amounts to 14.3% of revenue for EMN, versus a peer median of 10.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.51B | +17.7% | -50.0% | 8.2% | |
| LTM Jun 2026 | $1.27B | -26.3% | -7.6% | 14.3% | |
| LTM Jun 2026 | $690M | -14.9% | +13.9% | 19.0% | |
| LTM Sep 2026 | $684M | +41.6% | — | 6.0% | |
| LTM Sep 2026 | $506.9M | +19.1% | +16.5% | 14.8% | |
| LTM Sep 2026 | $466M | -1.9% | -13.5% | 13.4% | |
| LTM Jun 2026 | $380M | +176.5% | — | 20.6% | |
| LTM Jun 2026 | $181M | -12.7% | -7.0% | 9.8% | |
| LTM Mar 2026 | $139.93M | -27.5% | -10.3% | 6.0% | |
| LTM Sep 2026 | $136.5M | -4.9% | -56.0% | 12.1% | |
| LTM Mar 2026 | $124M | -68.4% | -44.9% | 2.2% | |
| Peer median (excluding EMN) | $423M | -3.4% | -11.9% | 10.9% | |
Competitors are the stored peer set for EMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.48B | 10.54B | 9.2B | 9.38B | 8.75B |
| Cost of Revenue | 7.97B | 8.48B | 7.14B | 7.09B | 6.91B |
| Gross Profit | 2.52B | 2.06B | 2.06B | 2.29B | 1.84B |
| Gross Margin | 24.0% | 19.5% | 22.4% | 24.4% | 21.1% |
| Research & Development | 254M | 264M | 239M | 250M | 255M |
| Selling, General & Admin | 795M | 708M | 727M | 664M | 658M |
| Operating Expenses | 1.05B | 972M | 966M | 914M | 913M |
| Depreciation & Amortization | 538M | 477M | 498M | 509M | 513M |
| EBITDA | 1.81B | 1.64B | 1.81B | 1.8B | 1.29B |
| EBITDA Margin | 17.3% | 15.5% | 19.6% | 19.2% | 14.7% |
| Operating Income | 1.47B | 1.08B | 1.1B | 1.38B | 931M |
| Operating Margin | 14.0% | 10.3% | 11.9% | 14.7% | 10.6% |
| Interest Income | 3M | 6M | 10M | 16M | 0 |
| Interest Expense | 192M | 188M | 225M | 216M | 208M |
| Other Income / Expenses | (387M) | (107M) | (9M) | (298M) | (363M) |
| Income Before Tax | 1.08B | 977M | 1.09B | 1.08B | 568M |
| Pre-Tax Margin | 10.3% | 9.3% | 11.8% | 11.5% | 6.5% |
| Income Tax Expense | 215M | 181M | 191M | 170M | 93M |
| Net Income | 857M | 793M | 894M | 905M | 474M |
| Net Margin | 8.2% | 7.5% | 9.7% | 9.6% | 5.4% |
| EPS (Basic) | 6.35 | 6.42 | 7.54 | 7.75 | 4.13 |
| EPS (Diluted) | 6.25 | 6.35 | 7.49 | 7.67 | 4.10 |
| Weighted Avg Shares | 134.9M | 123.5M | 118.6M | 116.7M | 114.7M |
| Weighted Avg Shares (Diluted) | 137.1M | 124.9M | 119.4M | 117.9M | 115.6M |
Eastman Chemical Company
NYSE:EMN
Intrinsic Alpha fair value
Locked
Current Price
$62.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.